Quantification of Intratherapeutic SPECT/CT for Lutetium-177-DOTATOC PRRT in Neuroendocrine Tumors Abstract #2917

Introduction: In PRRT for NET, feasibility of lesion uptake quantification in Lu-177-DOTATOC SPECT/CT for therapy monitoring remains unclear.
Aim(s): To evaluate association of lesion SUV, estimated lesion dose and response.
Materials and methods: Retrospective analysis in 10 NET patients undergoing first 2 PRRT cycles (activity: 7.0 [5.5-7.1] GBq). Max/peak/mean counts and metabolic tumor volume (MTV) of primary tumor (n=1) or metastases (liver: 16, extrahepatic: 9) were measured on Lu-177 SPECT/CT 24h p.i. at both cycles. SUV (max/peak/mean) were calculated based on volume sensitivity for a homogenous cylindrical phantom. Relative change of metabolic tumor load (product MTV*SUV) between 1st and 2nd cycle was correlated for each lesion to its relative change in maximum diameter (CT/MRI) and the estimated lesion dose (Gy). Response in patient-based analysis was defined by change in summed MTV*SUV for all target lesions between PRRT cycles following RECIST (PD: >+20%; PR: >-30%; SD: others).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Markus Galler

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2863 Introduction of Dosimetry on PRRT Practice. A Useful Tool to Detect Responders and Evaluate Treatment Safety
Introduction: PRRT is a recognized salvage option for G1-G2 GEPNET. Currently, the Italian protocol (Lutathera AIFA Guidelines) consists in four fixed-dose of 177 Lu-DOTATATE. The dosimetry has recently been recognized as an important tool to guide PRRT but is not yet part of routine practice.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: MD Federica Scalorbi
#2985 Peptide Receptor Radionuclide Therapy (PRRT) Outcome Prediction in Neuroendocrine Tumors (NET): Could Radiomic Features Analysis of 68Ga-DOTATOC PET/CT Have a Roll?
Introduction: The PRRT is an effective treatment for NET, but the selection of a good candidate is a very important step.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Virginia Liberini
#2996 A Head-to-Head Comparison between Two Software Packages for Hybrid Dosimetry after PRRT
Introduction: The number of dosimetry studies after PRRT is increasing, yet different methodologies are used which challenge comparison or pooling of results.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Daphne Huizing
#2849 PRRT Neuroendocrine Tumor Response Assessment Using Circulating Transcript Analysis: The NETest
Introduction: The absence of an accurate blood biomarker to predict and monitor PRRT is a key unmet need.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD, PhD Lisa Bodei
#2894 Single Institution Experience with Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
Introduction: Neuroendocrine tumors (NETs) are a rare and heterogenous group of tumors with rising incidence. Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogue is an encouraging systemic treatment modality with minimum side effects.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr. Heying Duan
Authors: Duan H, Ninatti G, Girod B, Ferri V, ...
Keywords: NET, PRRT, ORR, PFS